A research team has confirmed that brain amyloid-β (Aβ) deposition, a biomarker for Alzheimer’s disease, is an essential predictor for post-stroke cognitive impairment (PSCI) development and cognitive decline after small-sized cerebral infarction.
A research team has confirmed that brain amyloid-β (Aβ) deposition, a biomarker for Alzheimer’s disease, is an essential predictor for post-stroke cognitive impairment (PSCI) development and cognitive decline after small-sized cerebral infarction.